Review Article
A Meta-Analysis of 13 Randomized Trials on Traditional Chinese Medicine as Adjunctive Therapy for COVID-19: Novel Insights into Lianhua Qingwen
Table 1
The main characteristics of the randomized controlled trials are included in the meta-analysis.
| Author | Year | Country | Traditional Chinese | Sample | Patient average age (y) | TCM | Treatment | Ref. | Medicine (TMC) | Size | Control | Experiment | Dosage | Duration |
| Chen et al. | 2021 | China | Lianhua Qingwen capsules | 60 | | | 4 capsules, bid | 15 days | [12] | Hu et al. | 2020 | China | Lianhua Qingwen capsules | 284 | | | 6 g, tid | 7 days | [13] | Yu | 2020 | China | Lianhua Qingwen capsules | 295 | | | 4 capsules, tid | Not reported | [14] | Chen et al. | 2020 | China | Lianhua Qingwen capsules | 70 | | | 4 capsules, tid | 14 days | [15] | Xiao et al. | 2020 | China | Lianhua Qingwen capsules | 121 | | | 6 g, tid | 14 days | [16] | Fu et al. | 2020 | China | Toujie Quwen granules | 36 | | | Not reported, bid | 10 days | [17] | Fu et al. | 2020 | China | Toujie Quwen granules | 38 | | | Not reported, bid | 15 days | [18] | Xiao et al. | 2020 | China | Shufeng Jiedu capsules | 200 | | | 2.08 g, tid | 14 days | [19] | Wang et al. | 2021 | China | Qingfei Paidu decoction | 71 | | | 100 mL, bid | 10 days | [20] | Li and Zhang | 2020 | China | Qingfei Paidu decoction | 12 | | | 100 mL, bid | Not reported | [21] | Yang et al. | 2020 | China | Reyanning | 49 | | | Not reported | Not reported | [22] | Duan et al. | 2020 | China | Jinhua Qinggan granules | 62 | | | 10 g, tid | 5 days | [23] | Ding et al. | 2020 | China | Qingfei Touxie Fuzhengfang | 100 | | | 150 mL, bid | 10 days | [24] |
|
|